11M$ allocated to R&D over the next 31 month ...So pathetic that this Stockhouse editor is not even able to accept a basic cut&paste of a print screen!!!
Anyways, in support to LifeGoesOn1973's post, p. 27 of the prospectus also specifies this:
Management of Theralase currently expects to expend the $3,920,000 allocated to research and development related to the ACTNMIBC Study under the Minimum Offering over an approximate sixteenmonth period, and to expend the $11,000,000 allocated to research and development related to the ACTNMIBC Study under the Maximum Offering over an approximate 31month period.
And 140,000$ for the re-work of the TLC-2000.